SKN reports strongest quarter of sales to date
Australian owned and operated natural skin care company, Skin Elements Limited (ASX:SKN) has provided a positive December quarterly report showing growth, product development and increased sales — including its strongest quarter of sales to date totalling A$219,000.
That figure represents an increase of 71 per cent on the previous quarter, in part due to more sales via Australian distributors. This continued the strong and sustained quarter-on-quarter sales growth delivered by SKN since it first listed on the ASX in January 2017.
SKN currently has three distinct product ranges: the market leading Soléo Organics 100% natural and organic sunscreen, the Elizabeth Jane Natural Cosmetic skincare range, and the McArthur range of natural therapeutic skin care products (for common skin conditions).
The December quarter saw the company execute on its growth strategy of delivering sustained sales growth, taking steps towards entering new markets and ongoing product development.
It’s worth noting here that SKN is an early stage play and investors should seek professional financial advice if considering this company for their portfolio.
New online channel and more bolsters Soléo sunscreen sales
SKN’s lead product is its Soléo organic sunscreen which was the focus of a website launch in December intended to drive sales.
The new e-commerce website allows direct online sales capability and is expected to not only boost sales of Soléo sunscreen but the McArthur range of skincare products as well. The new online sales website is available via the Skin Elements company website or via this direct link.
During the quarter, the company also expanded its production capacity with a 20,000 tube production run of the sunscreen which was delivered during the quarter to meet growing demand.
A look at SKN’s balance sheet
In the report the company has advised shareholders it has been taking a shrewd approach to capital expenditure across the business, and has been in the process of evaluating cash inflows and operational spend requirements.
With a current cash balance of $651,000 at quarter’s end, combined with receivables totalling $107,000 and inventory to the value of $375,000 it is in a reasonable cash position. It also has a loan facility in place, with access to up to $550,000 available as required.
With sales moving consistently in the right direction over the last 12 months, SKN will be looking to fortify its cash position as it works towards increasing revenue and expanding its distribution footprint beyond Australia and New Zealand, to Europe, North America and Asia. It plans to update the market of material progress on its expansion efforts in the coming months.
New board appointment
During the quarter SKN welcomed Phil Giglia to the board as an Independent Non-Executive Director after the passing of Mr David Humann.
Giglia is a chartered accountant with over 30 years’ experience in accounting and a strong depth of taxation expertise in SMEs. He is also a registered tax agent and company auditor.
He is the founder of Perth accountancy practice, Giglia & Associates which specialises in providing accountancy advice to high net worth clients.
When the experts at Next Investors have a stock pick, it may pay to listen.
The Next Investors have been investing in ASX small cap stocks for years, with their best small cap picks yielding returns of 1,200%, 1,120%, 900% and 678%.
They have just revealed their hand-picked, FY2021 stock portfolio of high conviction long-term investments.
Click the link below to see what they are currently investing in.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.